Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

BACKGROUND: Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Ridker, Paul M, Everett, Brendan M., Pradhan, Aruna, MacFadyen, Jean G., Solomon, Daniel H., Zaharris, Elaine, Mam, Virak, Hasan, Ahmed, Rosenberg, Yves, Iturriaga, Erin, Gupta, Milan, Tsigoulis, Michelle, Verma, Subodh, Clearfield, Michael, Libby, Peter, Goldhaber, Samuel Z., Seagle, Roger, Ofori, Cyril, Saklayen, Mohammad, Butman, Samuel, Singh, Narendra, May, Michel Le, Bertrand, Olivier, Johnston, James, Paynter, Nina P., Glynn, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587584/
https://ncbi.nlm.nih.gov/pubmed/30415610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1809798
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados